The CoMPaSS-NMD Atlas is designed to generate a ripple effect of positive impact across the entire healthcare ecosystem.
For researchers and scientific communities
The Atlas provides an ethical, FAIR-aligned (Findable, Accessible, Interoperable, and Reusable) data environment. It empowers scientists to build highly specific patient cohorts, safely download structural reports, and pool resources to accelerate the development of effective treatments and cures.
For clinical centers
Thanks to the upload modules and the ATLAS capabilities, clinical centers can upload and manage their data in a secure, regulation-compliant and cost-free platform that aims to be the European Reference Database for NMDs.
For clinicians and pathologists
Clinical researchers gain a secure network where they can benchmark scientific findings against a larger pool of standardized data, easily consult detailed historical case registries, and review reference biopsy or imaging datasets from collaborating centers across Europe and the UK.
For the pharmaceutical and biomedical industry
The Atlas could also accelerate therapeutic innovation by simplifying the identification and recruitment of highly specific patient cohorts, significantly shortening clinical trial timelines.
Its standardized, machine-readable datasets, helping industry partners minimize development risks and design more effective, personalized treatments.
For healthcare policymakers
By establishing a successful model for multi-country, multi-center collaboration that respects strict European data governance guidelines, the Atlas provides a gold-standard framework. Policymakers can push for, adopt and adapt this infrastructure to improve rare diseases management, resources allocation, and clinical requirements at a structural level.
For patients and their families
By enabling researchers to cross-reference complex cases globally, the Atlas helps accelerate the understanding of rare neuromuscular conditions. Faster insights into genetic profiles mean quicker identification of eligible cohorts for clinical trials, clearer answers for families, and a stronger foundation for future personalized management strategies.